• Je něco špatně v tomto záznamu ?

IBCL-460 Subcutaneous Epcoritamab With Rituximab + Lenalidomide (R2) in Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Update from Phase 1/2 Trial

L. Falchi, S. Leppä, BE. Wahlin, M. Nijland, JH. Christensen, S. de Vos, H. Holte, KM. Linton, A. Abbas, L. Wang, M. Dinh, B. Elliott, D. Belada

. 2022 ; 22 Suppl 2 (-) : S392. [pub] -

Jazyk angličtina Země Spojené státy americké

Typ dokumentu klinické zkoušky, fáze I, klinické zkoušky, fáze II, časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22024246

CONTEXT: R/R FL is associated with a poor prognosis and remains incurable; thus, better treatment options are needed. Epcoritamab is a subcutaneously administered CD3xCD20 bispecific antibody that has shown substantial antitumor activity in R/R FL. OBJECTIVE: Evaluate safety and efficacy of epcoritamab with R2 in patients with R/R FL in arm 2 of a phase 1/2 open-label trial (EPCORE NHL-2; NCT04663347). PATIENTS: Adults with R/R CD20+ FL were included. As of December 1, 2021, 30 patients (median age, 68 y) had enrolled. INTERVENTIONS: Patients received subcutaneous epcoritamab (QW, cycle [C] 1-3; Q2W, C4-9; Q4W, C≥10 up to 2 y) + R2 for 12 cycles of 28 d. Step-up dosing and corticosteroid prophylaxis were required. RESULTS: Of the 30 patients (epcoritamab 24 mg, n=3; 48 mg, n=27), 21 (70%) had stage IV disease and 20 (67%) had FLIPI scores 3-5. Median (range) number of prior lines of therapy was 1 (1-5), 30% had primary refractory disease, and 40% had disease progression within 24 mo after starting first-line treatment. At a median (range) follow-up of 5.1 mo (0.8-12.3), 25 patients (83%) remained on treatment; 5 patients discontinued treatment due to progression (n=2), AEs (n=2), or consent withdrawal (n=1). Common treatment-emergent AEs (TEAEs) of any grade (G) included infections (57%), injection-site reactions (50%), constipation (37%), fatigue (37%), and neutropenia (37%). CRS events occurred in 15 patients (50%; G1-2 43%, G3 7%), primarily in C1. All CRS events resolved; 3 patients were treated with tocilizumab, and 1 patient discontinued treatment due to CRS. One patient experienced G2 ICANS. No fatal TEAEs occurred. Overall response rate for the 27 evaluable patients was 100%; 93% had a complete metabolic response (CMR) and 7% had a partial metabolic response by PET-CT. As of the data cut, the longest duration of response was 7.0+ mo and ongoing. CONCLUSIONS: Subcutaneous epcoritamab + R2 exhibits promising efficacy, including a high CMR rate, in patients with R/R FL. The safety profile was consistent with prior data. Updated data will be presented. FUNDING: This study was funded by Genmab A/S and AbbVie.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22024246
003      
CZ-PrNML
005      
20221031101348.0
007      
ta
008      
221017s2022 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/S2152-2650(22)01565-8 $2 doi
035    __
$a (PubMed)36164115
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Falchi, Lorenzo $u Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, USA
245    10
$a IBCL-460 Subcutaneous Epcoritamab With Rituximab + Lenalidomide (R2) in Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Update from Phase 1/2 Trial / $c L. Falchi, S. Leppä, BE. Wahlin, M. Nijland, JH. Christensen, S. de Vos, H. Holte, KM. Linton, A. Abbas, L. Wang, M. Dinh, B. Elliott, D. Belada
520    9_
$a CONTEXT: R/R FL is associated with a poor prognosis and remains incurable; thus, better treatment options are needed. Epcoritamab is a subcutaneously administered CD3xCD20 bispecific antibody that has shown substantial antitumor activity in R/R FL. OBJECTIVE: Evaluate safety and efficacy of epcoritamab with R2 in patients with R/R FL in arm 2 of a phase 1/2 open-label trial (EPCORE NHL-2; NCT04663347). PATIENTS: Adults with R/R CD20+ FL were included. As of December 1, 2021, 30 patients (median age, 68 y) had enrolled. INTERVENTIONS: Patients received subcutaneous epcoritamab (QW, cycle [C] 1-3; Q2W, C4-9; Q4W, C≥10 up to 2 y) + R2 for 12 cycles of 28 d. Step-up dosing and corticosteroid prophylaxis were required. RESULTS: Of the 30 patients (epcoritamab 24 mg, n=3; 48 mg, n=27), 21 (70%) had stage IV disease and 20 (67%) had FLIPI scores 3-5. Median (range) number of prior lines of therapy was 1 (1-5), 30% had primary refractory disease, and 40% had disease progression within 24 mo after starting first-line treatment. At a median (range) follow-up of 5.1 mo (0.8-12.3), 25 patients (83%) remained on treatment; 5 patients discontinued treatment due to progression (n=2), AEs (n=2), or consent withdrawal (n=1). Common treatment-emergent AEs (TEAEs) of any grade (G) included infections (57%), injection-site reactions (50%), constipation (37%), fatigue (37%), and neutropenia (37%). CRS events occurred in 15 patients (50%; G1-2 43%, G3 7%), primarily in C1. All CRS events resolved; 3 patients were treated with tocilizumab, and 1 patient discontinued treatment due to CRS. One patient experienced G2 ICANS. No fatal TEAEs occurred. Overall response rate for the 27 evaluable patients was 100%; 93% had a complete metabolic response (CMR) and 7% had a partial metabolic response by PET-CT. As of the data cut, the longest duration of response was 7.0+ mo and ongoing. CONCLUSIONS: Subcutaneous epcoritamab + R2 exhibits promising efficacy, including a high CMR rate, in patients with R/R FL. The safety profile was consistent with prior data. Updated data will be presented. FUNDING: This study was funded by Genmab A/S and AbbVie.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a protilátky bispecifické $x terapeutické užití $7 D018033
650    12
$a protokoly antitumorózní kombinované chemoterapie $x škodlivé účinky $7 D000971
650    _2
$a lidé $7 D006801
650    _2
$a lenalidomid $x terapeutické užití $7 D000077269
650    12
$a folikulární lymfom $x farmakoterapie $x patologie $7 D008224
650    _2
$a PET/CT $7 D000072078
650    _2
$a rituximab $x terapeutické užití $7 D000069283
655    _2
$a klinické zkoušky, fáze I $7 D017426
655    _2
$a klinické zkoušky, fáze II $7 D017427
655    _2
$a časopisecké články $7 D016428
700    1_
$a Leppä, Sirpa $u Helsinki University Hospital Comprehensive Cancer Center and University of Helsinki, Helsinki, Finland
700    1_
$a Wahlin, Björn E $u Karolinska Institutet, Stockholm, Sweden
700    1_
$a Nijland, Marcel $u University Medical Center Groningen and University of Groningen, Groningen, Netherlands
700    1_
$a Christensen, Jacob Haaber $u Odense University Hospital, Odense, Denmark
700    1_
$a de Vos, Sven $u Ronald Reagan University of California Los Angeles Medical Center, Los Angeles, USA
700    1_
$a Holte, Harald $u Oslo University Hospital and KG Jebsen Center for B-cell Malignancies, Oslo, Norway
700    1_
$a Linton, Kim M $u The Christie NHS Foundation Trust and Manchester Cancer Research Centre, Manchester, United Kingdom
700    1_
$a Abbas, Aqeel $u Genmab, Princeton, USA
700    1_
$a Wang, Liwei $u Genmab, Princeton, USA
700    1_
$a Dinh, Minh $u AbbVie, North Chicago, USA
700    1_
$a Elliott, Brian $u Genmab, Princeton, USA
700    1_
$a Belada, David $u 4th Department of Internal Medicine - Hematology, University Hospital and Faculty of Medicine, Hradec Králové, Czech Republic
773    0_
$w MED00180199 $t Clinical lymphoma, myeloma & leukemia $x 2152-2669 $g Roč. 22 Suppl 2, č. - (2022), s. S392
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36164115 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20221017 $b ABA008
991    __
$a 20221031101346 $b ABA008
999    __
$a ok $b bmc $g 1854135 $s 1175536
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 22 Suppl 2 $c - $d S392 $e - $i 2152-2669 $m Clinical lymphoma, myeloma & leukemia $n Clin Lymphoma Myeloma Leuk $x MED00180199
LZP    __
$a Pubmed-20221017

Najít záznam

Citační ukazatele

Možnosti archivace